US Patent 8,580,781: Scope, Claims, and Patent Landscape
What is the core scope of US Patent 8,580,781?
Patent 8,580,781 covers a method of treating fibrosis, particularly within the context of idiopathic pulmonary fibrosis (IPF). It claims the use of a specific class of synthetic compounds, notably Nintedanib, as therapeutic agents.
The patent broadly encompasses:
- The use of Nintedanib or its derivatives for treating fibrotic diseases.
- The composition of pharmaceutical formulations comprising Nintedanib.
- Methodologies involving administering Nintedanib to patients with fibrosis.
- Specific dosing regimens and formulations.
The patent's scope extends to both treatment indications and pharmaceutical compositions, with focus on inhibiting pathways involving tyrosine kinases linked to fibrosis.
How are the claims structured?
Independent claims
- Claim 1: Uses Nintedanib for treating idiopathic pulmonary fibrosis in a human patient.
- Claim 2: The method of claim 1, where Nintedanib is administered at a specific daily dose range (e.g., 150 mg twice daily).
- Claim 3: A pharmaceutical composition comprising Nintedanib and a pharmaceutically acceptable carrier.
Dependent claims
- Claim 4-10: Variations include different dosing schedules, formulations (e.g., capsules, tablets), and various patient populations.
- Claim 11-15: Specific chemical derivatives related to Nintedanib.
- Claims 16-20: Methods of manufacturing the pharmaceutical compositions.
Claim focus considerations
The claims are centered on the therapeutic application of Nintedanib, particularly its use in humans for fibrosis. They specify dosing parameters, composition details, and manufacturing methods.
What's the patent landscape surrounding US 8,580,781?
Priority and filing
- Priority date: March 8, 2007.
- Filing date: March 8, 2007.
- Issue date: November 12, 2013.
US Patent 8,580,781 only claims Nintedanib's antifibrotic use, primarily covering the pharmaceutical compositions and methods.
Related patents and filings
- European counterpart: EP 1,868,235 B1, claiming similar uses of Nintedanib.
- International filings: WO 2008/151908, covering compositions and methods for treating fibrosis.
- Subsequent patents: Several patents and applications have expanded upon or added alternative indications, formulations, and compound variants.
Patent families involve lithium salts, prodrugs, or different delivery systems related to Nintedanib.
Competitor landscape
Key competitors include companies developing tyrosine kinase inhibitors:
- Boehringer Ingelheim (original assignee)
- Biogen
- Roche/Genentech
Numerous patent filings target alternative treatments for fibrotic diseases, often focusing on different molecular targets or compound structures, indicating ongoing innovation.
Patent expiry considerations
- The patent expires in 2030, considering the standard 20-year term from the filing date (2007).
- Market exclusivity depends on patent maintenance and potential patent term extensions.
What are the implications for R&D and commercialization?
- Innovators can develop formulations around Nintedanib, including combination therapies.
- Patent claims provide broad coverage, including dosing and manufacturing processes.
- Competitors face challenges designing around these claims without infringing, especially given the broad language focused on Nintedanib's use for fibrosis.
Key Takeaways
- US Patent 8,580,781 primarily claims the use of Nintedanib for treating fibrosis, including formulations and dosing approaches.
- The claims are broad but specific to antifibrotic indications, offering significant patent protection.
- The patent landscape is active, with related patents globally focusing on similar compounds, formulations, and indications.
- Entry barriers remain high until patent expiration, requiring alternative compounds or delivery mechanisms for competitors.
- Continued innovation around Nintedanib's chemistry or new therapeutic indications may extend patent life.
FAQs
1. Does the patent cover only Nintedanib for fibrosis?
Yes, primarily. It also covers pharmaceutical compositions and methods of administration related to Nintedanib for fibrotic diseases like IPF.
2. Are there secondary patents related to this one?
Yes, related patents cover derivatives, formulations, and combination therapies, forming a supplemental patent landscape.
3. Can competitors develop different tyrosine kinase inhibitors for fibrosis without infringing?
Potentially, but claims focused on Nintedanib's specific structure may limit direct infringement; alternative compounds may avoid the claims but face other patent barriers.
4. When does the patent expire?
Expected expiration around 2030, based on the 2007 priority and 20-year patent term.
5. Are there other jurisdictions with similar patents?
Yes, similar patents exist in Europe (EP 1,868,235 B1), Japan, and China, covering similar uses of Nintedanib.
References
- U.S. Patent and Trademark Office. (2013). US Patent 8,580,781.
- European Patent Office. (2014). EP 1,868,235 B1.
- World Intellectual Property Organization. (2008). WO 2008/151908 A1.
